|
ORF cDNA clones
|
CRISPR / TALEN
|
Lentivirus
|
AAV
|
TALE-TF
|
ORF knockin clones
|
|
Antibody
|
Proteins
|
miRNA target clones
|
qPCR primers
|
shRNA clones
|
miRNA products
|
Promoter clones
|
Validated All-in-One™ qPCR Primer for SERPINE1(NM_000602.4) Search again
Product ID:
HQP088741
(click here to view gene annotation page)
Powered by BiozSpecies:
Human
Symbol:
Alias:
PAI, PAI-1, PAI1, PLANH1
Gene Description:
serpin family E member 1
Target Gene Accession:
NM_000602.4(click here to view gene page)
Estimated Delivery:
Approximately 1-3 weeks, but may vary. Please email sales@genecopoeia.com or call 301-762-0888 to confirm ETA.
Important Note:
By default, qPCR primer pairs are designed to measure the expression level of the splice variant (accession number) you selected for this gene WITHOUT consideration of other possible variants of this gene. If this gene has multiple variants, and you would like to measure the expression levels of one particular variant, multiple variants, or all variants, please contact us for a custom service project at inquiry@genecopoeia.com.
Validated result:
|
|
| A | B |
|
Each All-in-One™ qPCR Primer is experimentally validated to yield a single dissociation curve peak and to generate a single amplification of the correct size for the targeted gene. A cDNA Pool, containing reverse transcript products of 8 different human tissue total RNA(Liver, Testis,Muscle,Thyroid,Brain,Spleen,Stomach,Small Intestine)),was used as the qPCR validation template. qPCR was performed using 0.2 µM primer with 2XAll-in-One™ qPCR Mix (Catalog#: QP001,QP002,QP004,QP005). Reactions were incubated for 10min. at 95°C, followed by 40 cycles of 95°C for 10 sec.; 60°C, 20 sec. and 72°C, 15sec. using Bio-Rad iQ5™ Instrument. At the end of the last cycle, temperature was increased from 72 to 95°C to produce a melting curve. Panel A: Validated Result for Amplification Curve; Panel B: Validated Result for Melting Curve. |
|
Gene References into function
- p53 binds to and regulates the promoter of PAI-1.
- mean transit time, the net quantitative turnover rate, and the sites of synthesis and catabolism
- PAI-1 gene activation by TNF-alpha apparently is yet to be defined for the location of the response element and/or the signaling pathway. BAEC responded to TNF-alpha stimulation with activation of the MAP kinases and the NFkappaB transcriptional factors.
- Plasminogen activator inhibitor type 1 promotes the self-association of vitronectin into complexes
- Together with low birth weight, increased plasma PAI-1-act levels in early pubertal precocious pubarche may indicate a greater risk of developing hyperinsulinemic-hyperandrogenism features of polycystic ovary syndrome.
- the 4G/5G polymorphism may influence PAI-1 expression in obesity, with a crucial role in central but not peripheral adiposity.
- PAI-1/ tPA imbalance is associated with myocardial infarction at young age in Japanese men.
- The expression of PAI-1 protein and PAI-1 mRNA is increased in HCC and contributes to the invasion, metastasis and prognosis of HCC.
- Cell adhesion regulates plasminogen activator inhibitor-1 gene expression in anchorage-dependent cells; vitronectin and fibronectin, as components of ECM, may be the factors involved in the regulation of PAI-1 gene expression
- Increased PAI-1 levels were found from eary 2d trimester through labor and decreased after delivery. Elevated PAI-1 serves to counteract the enhanced fibrinolysis seen during labor.
- In children with sepsis-induced multiple organ failure, a cytokine-associated increase in circulating PAI-1 release & systemic activity was predicted. Increased PAI-1 activity was associated with cardiovascular, renal, and hepatic failure.
- Arsenite inhibited the thrombomodulin (TM) mRNA expression and reduced the TM antigen level in microvascular endothelial cells, but not umbilical vein endothelial cells, suggesting a role in Blackfoot disease, a peripheral vascular occlusive disease.
- Identification of a tightly regulated hypoxia-response element in the promoter of human plasminogen activator inhibitor-1.
- PAI-1 inhibits plasminogen activators by forming stable complexes endocytosed by LDL receptor superfamily mechanism and circulates in plasma and latently in platelets but is also secreted and deposited into matrix by cells to participate in tissue repair
- TGFbeta was the only growth factor tested that was able to exceptionally up-regulate PAI-1, mainly in dystrophic satellite cells rather than normal myoblasts.
- PAI-1 was determined in myocardial infarction and re-infarction patients along with other parameters relevant for the Syndrome X.
- polymorphic in graft dysfunction after renal transplantation
- a decreased risk of MI or stroke among young women carrying the 4G allele of the PAI-1 4G/5G polymorphism.
- The common -675 4G/5G polymorphism is strongly associated with obesity
- inhibition of Rho/Rho-kinase signaling downregulates the synthesis of PAI-1 in human monocytes
- Hypoxia enhances the expression of plasminogen activator inhibitor-1
- PAI-1 is induced by oncostatin M in lung tumor cells
- C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils.
- Hyperglycemic siblings of type II diabetic patients have increased blood levels, central obeisty and insulin resistance compared with their paired normoglycaemic sibling.
- PAI-1 also plays a pivotal role in progressive renal disease, both glomerulosclerosis and tubulointerstitial fibrosis.
- interactions between the fibrinolytic and renin-angiotensin systems play an important role in the genetic architecture of plasma t-PAI-1
- Human breast adenocarcinoma cell lines promote angiogenesis by providing cells with uPA-PAI-1 and by enhancing their expression.
- relationships among adult periodontitis, smoking, and a variation in the deletion/insertion (4G/5G) promoter polymorphism of the plasminogen-activator-inhibitor-1 (PAI-1) gene
- upregulation of PAI-1, uPA, and tPA after long-term LDL exposure seems to be mediated by a delayed PKC activation associated with an increased PA inhibitory activity
- study demonstrates that PAI-1 concentrations are higher in impaired glucose tolerance than in normal glucose tolerance subjects
- There was a positive correlation between uPA and PAI-1 antigen levels and clinicopathological parameters such as grade (p < 0.001 and p = 0.01, respectively)
- plasminogen activator inhibitor 1 (PAI-1) is converted by monoclonal antibodies to a substrate for tissue (tPA)- and urokinase plasminogen activators
- Both adipose tissue and blood PAI-1 levels were positively associated with TNFRSF1A and TNFRSF1B in obesity.
- Study of the association between 4G/4G and 4G/5G genotypes and the site of thrombosis suggests an association with thrombosis in vessels of internal organs especially in the portal veins.
- formation of an inhibited serpin-proteinase complex as a single concerted transition of the serpin structure
- plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G polymorphism is associated with coronary heart disease (CHD) in Chinese
- Oncostatin M and interleukin-1 regulate the PAI-1 gene expression via up-regulating c-fos levels and subsequent binding of c-fos/c-jun heterodimers to the proximal element of the PAI-1 gene.
- The morning increase in PAI-1 is more pronounced among homozygotes for the 4G allele compared with the other genotypes. Homozygosity for the 4G allele is associated with increased PAI-1 levels during the morning only.
- diurnal pattern in PAI-1 activity and t-PA in relation to the 4G/5G-polymorphism in the promoter of the PAI-1 gene
- findings suggest that PAI-1 plays a role in later (thrombotic) rather than an earlier (atherosclerotic) stage of cardiovascular disease process.
- REVIEW: studies defining the binding sites of vitronectin and PAI-1 and binding affinities in the formation of larger PAI-1/Vtn complexes.
- a genetic variant of the plasminogen activator inhibitor-1 (PAI-1) determines the risk of avascular osteonecrosis in glucocorticoid-treated patients.
- In health centenarians plasma PAI-1 not associated with degree of insulin resistance. Analysis of genotype did not explain PAI-1 levels.
- hypoxia increased PAI-I mRNA levels in both normal peritoneal fibroblasts and adhesion fibroblasts
- small, hormone-receptor-positive breast cancers (with a theoretical good prognosis) may carry an elevated risk of nodal involvement if accumulation of uPA-PAI-1 complexes is shown inside their tumour cells by means of immunohistochemistry.
- the PAI-1 level and the Chalkley count are independent prognostic markers for recurrence-free survival in patients with primary breast cancer, suggesting that the prognostic impact of PAI-1 is not only based on its involvement in angiogenesis.
- Elevated PAI-1 levels are associated with target organ damage in subjects with newly diagnosed arterial hypertension.
- Increased PAI-1 levels were significantly related to insulin resistance in a Japanese general population. PAI-1 levels are associated with insulin resistance, irrespective of obesity.
- Induction of PAI-1 by exposure of lung epithelial cells to uPA is a newly recognized pathway by which PAI-1 could regulate local fibrinolysis in lung inflammation or neoplasia
- hypoxia-dependent plasminogen activator inhibitor 1 expression is regulated by MAP kinases
- 4G/4G genotype associated with elevated plasma PAI-1 in Chinese with and without hypertension. Contribution of PAI-1 genotype seemed larger in women. In hypertensives carrying the 4G/4G genotype, higher TG was correlated with higher PAI-1.
- High expression of plasminogen activator inhibitor, type I is associated with melanoma
- evidence that locking PAI-1 in a transition state between active and latent conformations is associated with a displacement of alphahF, subsequently resulting in substrate behavior
- This article maps the epitopes of a monoclonal antibody protecting this inhibitor against inactivating agents.
- The data presented identify new determinants of this inhibitor's latency transitions and provide general insight into the characteristic loop-sheet interactions in serpins.
- Distortion of autocrine transforming growth factor beta signal accelerates malignant potential by enhancing cell growth as well as PAI-1 and VEGF production in human hepatocellular carcinoma cells.
- findings indicate that the LDL particles that reach the subendothelial space can induce an increased release of PAI-1 by endothelial cells into the vessel lumen
- Increase of this protein in keloid fibroblasts may account for their elevated collagen accumulation in fibrin gel cultures.
- The expression of PAI-1 was significantly correlated with gastric tumor size, depth, lymph node involvement, differentiation, &vascular invasion.
- Ethnic differences in the PAI-1 4G/5G polymorphism along with corresponding differences in circulating PAI-1 levels were determined
- plasminogen activator inhibitor-1 production was significantly higher in omental than in subcutaneous adipose tissue and in obese subjects was higher than in non-obese subjects in both subcutaneous and in omental adipose tissue
- Transforming growth factor-beta1 produced by ovarian cancer cell line HRA stimulates attachment and invasion through an up-regulation of plasminogen activator inhibitor type-1 in human peritoneal mesothelial cells.
- Induction of PAI-1 gene expression is cell adhesion dependent and is through PI-3 kinase and Akt activation.
- increased PAI-1 activity in children with stable renal transplants is determined both by genetic factors and by metabolic factors, the latter mainly linked to the insulin resistance syndrome.
- no evidence that subjects with 4G/4G polymorphism have higher PAI-1 levels on admission or 6 months after acute myocardial infarction. Levels of PAI-1 are related to concentrations of proinsulin-like molecules and of proinflammatory cytokines.
- CO2 increased mesothelial cell PAI-1 expression involving a transcriptional mechanism. These findings might provide a mechanism for adhesion formation and cancer progression following laparoscopic surgery.
- results strongly support that sTNF up-regulates in an autocrine manner PAI-1 and MMP-9 syntheses during promyelocyte to monocyte differentiation; in more advanced differentiated stages, released sTNF is not a major determinant of PAI-1 and MMP-9 synthese
- Gelsolin and plasminogen activator inhibitor-1 have roles as Ap3A-binding proteins
- PAI-1 polymorphisms interact with known environmental risk factors (chronic hyperglycaemia, obesity, etc.) to induce a more severe insulin-resistant metabolic profile in overweight subjects, and to further increase risk for CHD in diabetic subjects.
- PAI-I modulates glioma cell invasion and motility through extracellular matrix components
- first study to quantify discrete plasminogen activator inhibitor-1 elevations that persist in the setting of polycystic ovary syndrome even with normal or low ambient insulin levels
- hypofibrinolytic genotypes of the PAI-1 gene are associated with the occurrence of mild preeclampsia
- The induction of increased PAI-1 expression in human arterial smooth muscle cells by growth factors implicated in accelerated atherogenesis is independent of the PAI-1 4G/5G polymorphism.
- Lys(88), Asp(89), Lys(176) & His(229) are the major residues of the PAI-1 conformational epitope. Lysine(88) & aspartic acid(89) are on the loop between alpha-helix D & beta-strand 2A. They undergo big conformational changes during latency conversion.
- PAI-1 expressed recombinantly or naturally by human cell lines displays heterogeneous glycosylation pattern of sites at N209 and N265, while that at N329 is not utilised.
- PAI-1 appears to stabilize the chemoattractant form of IL-8 at the cell surface, prevents shedding of proteoglycan, and maintains the chemoattractant gradient in cultured vascular endothelial cells.
- PAI1 polymoprhism in the promoter region is not associated with the risk of cardiovascular disease
- During infusion of triacylglycerol, PAI-1 increased to approximately 2.6 fold higher levels while tPA and adipsin were unaffected; changes in sVCAM-1 were significantly correlated with those seen for PAI-1.
- PAI-1 4G/5G promoter polymorphism alone is not associated with ischemic stroke.
- plasminogen activator inhibitor-1 distorts the catalytic domain of tissue-type plasminogen activator leading to the formation of stable serpin-proteinase complexes
- agonists of PPAR alpha increased basal and insulin-stimulated PAI-1 antigen release with a mechanism involving gene transcription and requiring signaling through the ERK1/2 signaling pathway
- PAI-1 and IL-8 secretion are increased by glucose
- PPARgamma can reduce plasminogen activator inhibitor type 1 production in vascular endothelial cells directly by repression of transcription.
- homozygosity for the ACE D allele is a risk factor for recurrent spontaneous miscarriages(RM); homozygosity for the ACE D and PAI-1 4G alleles additionally amplifies the RM risk; this may be exerted by their common effect to increase PAI-1 expression
- Our results support a protective effect of the PAI-1 4G allele against stroke; notable given the direct relationship between stroke and PAI-1 activity. We hypothesize that local increase in tissue PAI-1 associated with the 4G allele may stabilize plaques
- These results are the first to demonstrate that an orally active PAI-1 inhibitor can reduce plasma PAI-1 activity while maintaining normal platelet aggregation and coagulation.
- This study suggests that PAI-1 has a role in risk of MI in the presence of underlying insulin resistance. A significant interaction between insulin or proinsulin and the -675 4G/5G polymorphism was observed in risk for MI.
- the transcriptional response of the endogenous mPAI-1 promoter varies widely in terms of tissue specificity and magnitude of response to specific stimuli, angiotensin II, tgf-beta1, and LPS
- PAI-1 polymorphism in the promoter region is not a risk factor for myocardial infarction in Caucasians with type 2 diabetes mellitus.
- PAI-1:Ag levels were higher in symptomatic thrombophilia patients and related to the 4G/5G polymorphism, with significantly higher values in the 4G/4G carriers.
- MEK1,2 response element that mediates angiotensin II-stimulated PAI-1 promoter activation and shows that activation of this element requires Sp1 and AP-1 co-activation.
- The cleavage and inactivation of PAI-1 by generated thrombin is proposed to be responsible for the shortening of clot lysis time by Ca2+ and for coagulation-associated over-expression of fibrinolysis, which was suppressed by aPC.
- Type 1 plasminogen activator inhibitor (PAI-1) 4G/5G gene polymorphism might affect the plasma PAI-1 levels related to exhaustion severity. With the 5G/5G polymorphism, exhausted subjects might have less fibrinolytic capacity than non-exhausted subjects.
- Genotypes of PAI-1 4G/5G and MTHFR C677T or plasma concentrations of PAI-1 had no effect on the incidence of ONFH in Japanese subjects.
- uPA:PAI-1 complex independently predicts the efficacy of adjuvant chemotherapy in patients with primary breast cancer.
- Upon reactive center loop cleavage and loop insertion into the body of PAI-1, resonances assigned to Trp86 and Trp139 undergo large downfield chemical shifts consistent with major changes observed in the crystal structures of active and cleaved PAI-1.
- identified a 5' distal TNFalpha-responsive enhancer of the PAI-1 gene located 15 kb upstream of the transcription start site containing a conserved NFkappaB-binding site that mediates the response to TNFalpha.
- PAI-1 may have a role in metastasis of esophageal squamous cell carcinoma
- PAI-I has roles in the pathogenesis of cardiovascular disease [review]
- PAI-1 has roles in tumour growth, invasion, and metastasis [review]
- uPA and PAI-1 have roles in progression and recurrence of breast cancer [review]
- urokinase-type plasminogen activator (uPA) and type-1 inhibitor (PAI-I) complex has a role in breast cancer resistance to endocrine therapy independent of steroid hormone receptor status
- The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1
- Blood levels not altered in HIV patients, with or without HAART.
- indication that PAI-1 gene is a direct target of EPAS1 and suggest the role of EPAS1 and Sp1 in the hypoxic response of cancer cells
- MMP-13, uPA, and PAI-1 antigen levels were determined in the synovium of patients with osteoarthritis
- plasminogen activator inhibitor type 1 is required for the regulation of plasminogen activator-dependent, plasmin-independent processes, and expression critically modulates inflammation--REVIEW
- REVIEW of factors which influence PAI-1 levels and the possible role of PAI-1 polymorphisms in the acute phase response and cardiovascular diseases
- Multiple logistic regression analysis identified sex, angina pectoris, and PAI-1 as independent determinants of hyperadiponectinemia
- PAI-1 mutants inhibit neutrophil elastase and cathepsin G
- the in vitro migratory and invasive phenotype in breast and ovarian cancer cell lines is reduced by active PAI-1 due to its ability to inhibit plasminogen activation.
- Sphingosylphosphorylcholine induces PAI-1 production through a G protein-coupled calcium increase and downstream kinase signaling events in cultured human dermal fibroblasts.
- plasminogen activator inhibitor-1(PAI-1) genotypic subtypes 4G/4G and 4G/5G in polycystic ovary syndrome(PCOS) were present with a statistically higher frequency and PCOS women had higher levels of PAI-1
- Gly-BSA increases DNA binding activity of Smad3 and that it stimulates PAI-1 transcription through Smad-binding CAGA sequences in the PAI-1 promoter in human mesangial cells
- no significant association between homozygosity for PAI-1 4G4G and risk of retinal vein occlusion
- ERalpha activates the PAI-1 promoter through a proximal ERE (-427) & possibly additional EREs. ERbeta suppresses the promoter construct via an unidentified mechanism.
- in vitro assays of basal transcription suggest no difference in the binding of nuclear proteins to the promoter and no difference in the transcriptional activities of the alleles of the PAI-1 4G/5G polymorphism
- Recent large Japanese case-control studies identified connexin-37 (GJA-4), plasminogen activator inhibitor-1 (PAI-1), and stromelysin-1 (MMP-3) polymorphisms as risk factors for myocardial infarction.
- Data describe the cyclic variation and distribution of urokinase plasminogen activator (uPA), uPA receptor and plasminogen activator inhibitor 1 (PAI-1) mRNA in normal endometrium.
- During weight loss, after gastric restrictive surgery, inflammatory mediators remain elevated for at least 3 months. postoperatively, suggesting initially an ongoing inflammatory state.
- Data showed no significant differences in PAI-1 gene haplotypes distribution were seen between coronary artery disease patients and control subjects.
- The distribution of PAI-1 promoter 4G/5G polymorphism in Chinese differs from that in Caucasians. PAI-1 promoter 4G/5G polymorphism does not alter basic transcription activity and 4G promoter has increased response to IL-1.
- 4G/5G polymorphism of the PAI-1 gene might be associated with low-density lipoprotein particle size
- continuous production of large amounts of active PAI-1 in platelets
- Calcium appeared to have a critical role in the regulation of the HIF system and subsequent activation of the PAI-1 gene expression.
- The 4G-allele of the PAI-1 gene is not consistently associated with a higher prevalence of coronary stenosis.
- Unregulated plasmin hyperactivity due to decreased inhibition by PAI-1 may play an important role in coronary aneurysm formation.
- Upstream elements are important regulators of growth factor-initiated PAI-1 transcription (as predicted from the identification of PAI-1 as a direct upstream factor target gene) and the associated epithelial migratory response
- PAI-1, via interaction with both Act-4 and uPA, may function as a modulator of the mononuclear phagocyte response, not only in inflammation but also in tumor invasion and metastasis.
- TGF-beta-stimulation of transcription of PAI-1 is inhibited by VEGF, and TGF-beta phosphorylation of Smad2/3, an obligatory step of intracellular TGF-beta signaling, is suppressed by VEGF
- PAI-1 mRNA was detected in 13 of 16 prostatisc carcinomas and in 8 of 9 benign hyperplasias.
- PAI-1 levels and activity were increased in lean polycystic ovary syndrome women and these were directly correlated with insulin resistance.
- In patients with type 2 diabetes mellitus, the PAI-1 4G/5G promoter polymorphism does not predict PAI-1 plasma levels and is not associated with common metabolic parameters besides fibrinogen levels.
- elevated PAI-1 activity may be a factor in the increased cardiovascular morbidity seen in polycystic ovary syndrome
- CysPAI-1 proteins significantly diminished the mean sprout area
- PAI-1 production by endothelial cells is affected differently by calcitriol and paricalcitol
- plasminogen activator inhibitor-1 has roles in wound healing, atherosclerosis, metabolic disturbances, tumor angiogenesis, chronic stress, bone remodeling, asthma, rheumatoid arthritis, fibrosis, glomerulonephritis and sepsis [review]
- VEGF and PAI-1 interact and may have roles in progression of node-negative breast cancer
- A proteolytic effect for PAI-1 regulates cell invasiveness in desmoid tumor.
- These data demonstrate that TNF-alpha rather than IL-6 stimulates an increase in PAI-1 mRNA in the subcutaneous adipose tissue, suggesting that TNF-alpha may be involved in the pathogenesis of related metabolic disorders.
- healthy persons and patients with previous myocardial infarction differed regarding coronary risk factors associated with PAI-1
- the level of Smad6s can alter the level of TGF-beta and the subsequent induction of PAI-1 via a FoxD1 transcription site
- IL-6 increases hepatic PAI-1 expression mediated by the -232- to -210-bp region of the promoter containing a C/EBPdelta binding site.
- Recent data in this review suggest that PAI-1 contributes directly to the complications of obesity, including type 2 diabetes, coronary arterial thrombi, and may even influence the accumulation of visceral fat.
- Reactivve oxygen species production, NAD(P)H oxidase activity, mitochondrial membrane potential, AP-1 activity, PAI-1 mRNA expression, and proliferation and migration of human vascular smooth muscle cells.
- basic capacity of separated epithelial and stromal cells from all three types of tissue to release uPA, PAI-1, and suPAR without any paracrine influence, as in vivo
- Positive association of IL-6 GG genotype with hypertension and elevated plasma PAI-1 in normotensive individuals in Chinese in Taiwan. IL-6 gene promoter G-174C polymorphism may affect regulation of PAI-1 and blood pressure through inflammatory mechanism
- IL-6 and OSM upregulate PAI-1 protein and mRNA in adipose tissue
- review discusses the discovery, origin, properties and regulation of PAI-1, and then speculates about its potential role in vascular disease, fibrosis, obesity and the metabolic syndrome, and cancer.
- the G20210A prothrombin gene mutation and the PAI-1 5G/5G genotype have roles in early onset of severe preeclampsia
- cellular iron status regulates the expression of PAI-1 via mRNA stability and subsequently the cell-surface plasmin activity in cultured human lung fibroblasts
- PAI-1 levels are elevated in android obesity, which suggests that increased oxidative stress may represent a biochemical link between android obesity and an increased risk for cardiovascular disease
- The level of type I plasminogen activator inhibitor-1 (PAI-1) does not correlate with cerebrospinal fluid to serum albumin ratio, suggesting an unimportant role for PAI-1 in HIV-induced blood-brain-barrier disruption.
- Complexation with vitronectin, with a sedimentation coefficient of 6.5 S, is the key intermediate for the assembly of higher order complexes.
- The tissue plasminogen activator inhibitor-1 protein(PAI-1) antigen levels were significantly and positively correlated with tumor severity and tumor size.
- function, clinical and prognostic role of PAI-1 in gynaecological malignancies (REVIEW)
- The levels of P-selectin, tPA antigen, and PAI-1 activity were all significantly higher in stroke patients compared with controls.
- mast cell-derived exosomes via significant upregulation of PAI-1 secretion from endothelial cells may provide feedback between the characteristically increased PAI-1 levels and procoagulant states
- in a model system, TGF beta-1 released from activated platelets contributes to the hemostatic imbalance at the sinusoidal endothelium in patients with hepatic VOD by increase of endothelial cell PAI-1 production and TF expression.
- EMSA revealed the presence of a nuclear protein binding to the 3'-UTR of PAI-1 mRNA in an iron-mediated manner. Iron-mediated mRNA-protein interaction in PAI-1 is involved in mRNA stability and PAI-1 regulation
- Findings suggest that genetic polymorphisms of plasminogen activator inhibitor-1 gene 4G/5G and 5,10-methylenetetrahydrofolate reductase C677T were associated with recurrent early spontaneous abortion.
- PAI1 is downregulated by vitamin D analogs in human coronary artery smooth muscle cells
- The observations suggest TZDs inhibit TNFalpha-mediated PAI-1 induction independent of inducible PPARgamma activation.
- Hypoxia induces PAI-1 expression via remarkable nuclear accumulation of HIF-1alpha and partially via NF-kappaB activation and TNF-alpha can synergistically enhance this hypoxia-induced PAI-1 expression
- there is a true and clinically important association between PAI-1 4G/5G genotype and risk of future ischemic stroke
- PAI-1 release was not significantly decreased relative to N-LDL in cells incubated with low concentrations of highly oxided LDL(HO-LDL) and glycated LDL (HOG-LDL), but was decreased for HO-LDL and HOG-LDL
- PAI-1 promoter haplotype and body mass index affect PAI-1 concentrations and body mass index is a stronger determinant than PAI-1 promoter variation.
- variant frequencies of ICAM1, APOE, PPARA and PAI-1 genes in coronary artery disease patients and healthy blood donors; specific arrangement of polymorphic variants which differentiate both groups
- discussion of the role of PAI-1 in atherothrombosis [review]
- The 5G/4G polymorphism of the PAI1 promoter is not associated with occurrence and phenotype of the polycystic ovary syndrome
- Elevated plasma levels in, and therefore a marker for cancers.
- Metabolic syndrome and hypercholesteremia synsynergistically accelerates inflammation and impairment of fibrinolysis via elevated concentrations of PAI-1, which inhibit fibrinolysis.
- LPS increased PAI-1 expression in the lung and alveolar compartment; a role for PAI-1 in the JNK-mediated pathway regulating LPS-induced neutrophil recruitment was eluciated
- in cells from insulin resistant individuals, insulin action to stimulate atherogenic processes, such as PAI-1 release, is preserved
- NO and PAI-1 play pivotal and antagonistic roles in hepatic vein thrombosis
- Three sequence variants at the PAI-1 locus explain approximately 5% of the residual variance in multivariable-adjusted PAI-1 levels.
- neither the tPA -7351C>T nor the PAI-1 to 675 4G>5G polymorphism show significant association with ischemic stroke, but the tPA CC/PAI-1 4G4G genotype combination may have a protective effect
- PAI-1 directly bound to the alpha(20-88) and thus concentrated in fibrinogen/fibrin
- the 4G/5G insertion/deletion promoter polymorphism, which leads to differences in PAI-1 production, has been demonstrated to affect risk of developing severe complications and dying from sepsis during meningococcal infection and multiple trauma [review]
- PAI-1, besides its uPA inhibiting function, has a role in cancer progression by protecting tumor cells from undergoing apoptosis
- PAI-1 can be bound to Tbeta4-activated endothelial cells, thus influencing their adhesive properties as well as their ability to generate plasmin
- Induction of SERPINE1 expression by TNF-alpha in endothelial cells is mediated by its responsive element located in the 4G/5G site.
- There is a close relationship of the PAI1 4G/5G polymorphism to its plasma level in deep vein thrombosis in Chinese Han ethnic group.
- Acetylglucosamine glycosylation is obligatory for glucose induced PAI-1 gene expression and Sp1 transcriptional activation in mesangial cells.
- Our results suggest that PAI-1 is a novel potential marker of initial invasion in oral SCC, and that the coordinated expression of PAI-1 with uPAR and lam-gamma2 sustain the features of the early invasive cancer cells.
- Low PAI-1 activity is common in patients with a bleeding diathesis, but it is a risk factor of minor clinical importance and not associated with specific bleeding manifestations
- Patients homozygous for allele 4G had a significantly higher risk of diabetic proliferative retinopathy than patients without signs of diabetic retinopathy or nonproliferative retinopathy.
- SRC-1 and GRIP-1, act as both corepressors of the glucocorticoid repression of PAI-1 gene transcription, and coactivators of TGFbeta-induced activation of the PAI-1 promoter.
- Foxc2 is a key molecule to regulate PAI-1 gene expression.
- pattern of PAI-1 4G/5G polymorphism might represent a useful marker of increased risk for pre-eclampsia
- Homozygosity for the 5G allele is associated with normal glucose tolerance in pregnant women.
- The 4G/4G genotype can increase the risk of thromboembolic neurological complications after cardiac surgery with cardiopulmonary by-pass
- In EH p22(phox) and PAI-1 mRNA and protein level was increased compared with C. In EH + D, doxazosin reduced p22(phox) and PAI-1 gene and protein expression, which was similar to that of C.
- thrombin-dependent inactivation of plasminogen activator inhibitor type 1 is enhanced more by unfractionated heparin than by low molecular weight heparin
- PAI-1 transcription occurred early after serum stimulation of quiescent (G0) keratinocytes and prior to entry into a cycling G1 condition
- downregulation of PAI-1 significantly enhanced the ability of endothelial cells to adhere to vitronectin, and this effect could be reversed upon addition of recombinant PAI-1
- it was concluded that PAI-1 promoter polymorphism 4G -> 5G (rs1799899) is not associated with the aggressiveness of disease in prostate cancer
- The rebound effect in serum PAI-1 concentration observed after streptokinase treatment may be related to the 4G/5G polymorphism in the PAI-1 gene promoter.
- In the current study, the impact of growth hormone (GH) and interleukin (IL)-6 on PAI-1 mRNA synthesis and secretion was determined in 3T3-L1 adipocytes.
- findings suggest that the 4G allele, by resulting in higher PAI-1 expression, is a major contributing factor in early stages of oral oncogenesis
- MTHFR, eNOS, PAI-1 polymorphisms are susceptibility loci and genotypes of these genes are neither necessary nor sufficient for the coronary artery disease to occur, but coexistence of high-risk alleles may increase the severity of coronary artery disease
- Results concllude that elevated PAI-1 levels may be associated with an increased risk for diabetes as a marker for underlying endothelial dysfunction rather than by a direct effect of genetically mediated elevated levels.
- Site-directed mutagenesis studies suggest that clock genes act on two canonical E-boxes to regulate PAI-1 promoter activity.
- C5a and its receptor have roles in PAI-1 production
- the 4G/5G PAI-1 genotype influences the PAI-1 response to IL-1alpha and the modulatory effect of pravastatin
- Data suggest that the 4G/5G polymorphism of PAI-1 is not a risk factor in IgA nephropathy etiology, but may facilitate the process of IgAN to end stage renal disease.
- HGF-mediated PAI-1 production may provide a novel link between atherothrombosis and metabolic derangements. Targeting HGF signaling pathway may modulate the thrombotic risk in high-risk patients.
- IL-1 and IL-6 exert directionally similar effects on PAI-1 expression, but the induction involves distinct signaling pathways with a final common mediator, C/EBPdelta.
- high PAI-1 mRNA expression represents a strong and independent unfavorable prognostic factor for the development of metastases and for breast cancer specific survival in a population of hormone receptor- and lymph node-positive breast cancer patients
- analysis of of an equilibrium between active PAI-1 and a pre-latent form, characterized by reversible detachment of s1C and formation of a glycan-shielded cleft in the molecule
- The PAI-1 4G/5G polymorphism may be a prognostic marker for young and middle-aged Chinese breast cancer patients.
- plasmin-mediated apoptosis of VSMC occurs via plasminogen activation by either t-PA or u-PA and is impaired by PAI-1.
- Variants in genes for PAI-1 (4G>5G) are not associated with low BMD in postmenopausal Czech Caucasian females.
- local factors, such as CTGF and genomic amplification, seem to be more important than germ line genetic variation in influencing PAI1 expression and its untoward effects in breast cancer
- In cancer cells PAI-1 is able to induce in vitro cell behaviour modifications, morphological changes, and to promote cell migration.
- Our results suggest that platelet TSP-1 released in a wound stimulates endothelial cell tubulogenesis through an upregulation of DF VEGF expression and a downregulation of endothelial cell PAI-1 expression.
- There was a trend towards association of the 4G allele (associated with high PAI-1 expression) with the development of aggressive fibromatosis in familial adenomatous polyposis patients (50% vs. 19%, P = 0.1).
- The 4G allele is associated with higher PAI-1 levels, but this study does not support an association of the PAI gene polymorphisms with the risk of either myocardial infarction or stroke.
- the PI3K/Akt pathway acts as a negative regulator of PAI-1 expression in vascular endothelial cells, in part, through the downregulation of MAPK pathways
- The inhibition of the nuclear factor-kappaB signaling pathway may be involved in the downregulation of PAI-1 gene expression by fenofibrate
- This study suggests that ILK serves as a key mediator in TGFbeta1 regulation of uPA/PAI-1 system critical for the invasiveness of human ovarian cancer cells. And ILK is a potential target for cancer therapy.
- association between TNFRSF1A +36G/G genotype and the MetS renders obese women more prone to activation of the TNF pathway reflected by high circulating sTNFR1 and PAI-1 levels.
- PAI-1 overexpression in esophageal and colorectal cancers might originate from higher PAI-1 expression in corresponding normal tissues and result in a malignant phenotype of these cancers
- These results support the idea that the interplay between the renin-angiotensin, bradykinin, and fibrinolytic systems might play an important role in t-PA and PAI-1 biology.
- In vitro shear stress can inhibit PAI-1 secretion by human endothelial progenitor cells.
- PAI-3, but not PAI-1 or uPA, may have a role in breast cancer survival by suppression of tumor invasion through protease inhibition in stroma
- HSF-1 is involved in glycated LDL-induced upregulation of PAI-1 in vascular endothelial cells through binding of HSF1 to PAI-1 promoter.
- novel pool of PAI-1 exists that is vulnerable to inhibition by inactivators that bind at the vitronectin binding site
- Upregulation of plasminogen activator inhibitor (PAI) expression during early development of knee osteoarthritis (OA) occurs via MAPK ERK, JNK, and p38 signaling pathways and the PI3K signaling pathway in cultured cells debrided from OA knees.
- Polymorphism in Plasminogen activator inhibitor -1 is associated with breast cancer
- Elevated plasma PAI-1 activity was independently associated with coronary microvascular dysfunction, which suggests that plasma PAI-1 activity is an important clue linking hypofibrinolysis to the development of atherosclerosis.
- Therefore, changes in actin cytoskeleton modulate the ability of TGF-beta1 to stimulate PAI-1 expression through a mechanism dependent on the activation of MAPK/AP-1 pathways.
- The 4G/4G plasminogen activator inhibitor-1 genotype appears to be associated with an elevated relative risk of developing arterial hypertension.
- Polyphenols repress EC PAI-1 expression, in part, by activating ERK and JNK signaling pathways and this repression is at transcriptional levels.
- TAFIa, PAI-1 and alpha-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots
- The activation of the neutrophil elastase-mediated fibrinolytic pathway may be insufficient to overcome the fibrinolytic shutdown by PAI-1 and may in part explain the poor prognosis of DIC patients associated with systemic inflammation.
- Fibrinogen and fibrin modulate the activity of tPA differently in regard to their activation of plasminogen and inhibition by PAI-1
- metabolic syndrome Indian and African indiviudals with 4G/5G and 5G/5G PAI-1 promoter genotypes have significantly higher plasma levels of plasminogen activator inhibitor type 1 (PAI-1)
- Our findings suggest that risk of glomerular microthrombosis in lupus nephritis is attributable, at least in part, to an epistatic effect of PAI-1 and FGB genes.
- postprandial glucagon was independently associated with PAI-1/t-PA in normal glucose tolerance
- higher BMI explained a significant proportion of the variance in the relationship between depressed sympathetic and parasympathetic activity and elevated plasma PAI-1 concentration
- PAI-1 has a role in controlling the biology of adipose tissue [review]
- A link is found between PAI-1 genotype, gene expression and incidence of coagulopathy after cardiac surgery.
- Altered expression of PAI-1 was observed in high-risk soft tissue sarcomas.
- Factor activator-like protein hyaluronan-binding protein 2 inhibits vascular smooth muscle cell proliferation in acute respiratory distress syndrome.
- homozygosity for 4G of the PAI-1 gene confers an increase in the risk of mortality in adult patients with septic shock due to a greater organ failure
- the 4G allele of PAI-1 appears to increase the risk of venous thrombosis, particularly in subjects with other genetic thrombophilic defects - meta-analysis
- PAI-1 induces cell detachment, downregulates B23 and TCTP in LnCAP prostate cancer.
- The common promoter -675 4G/5G indel of the PAI-1 gene is not associated with PP but, in Catalan young women, the 5G allele enhances the risk for insulin resistance imposed by the sequence of a low birth weight (LBW) and a high BMI.
- The urokinase plasminogen activator (BamHI) and plasminogen activator inhibitor type 1 (HindIII) genotypes may serve as useful markers for heritability of bone loss associated with periodontal disease.
- studied 160 healthy unrelated Lebanese individuals using a reverse hybridization PCR assay to detect the 5G/5G, 4G/5G and, 4G/4G genotypes of the PAI-1 gene and the frequencies of the 4G and 5G alleles
- the insertion/deletion (4G/5G) polymorphism of the plasminogen activator inhibitor type-1 gene affects the risk for ischemic stroke. We failed to demonstrate a significant association between the 4G/5G polymorphism and ischemic stroke.
- No evidence for plasminogen activator inhibitor 1 4G/4G genotype as risk factor for cerebral venous thrombosis.
- Elevation in PAI-1 in transgenic mice contributes to the development of polycystic ovary syndrome.
- If the effect of oncostatin M on PAI-1 in smooth muscle cells is operative in vivo, it could, via fibrinolysis and proteolysis, be involved in plaque progression, destabilization, thrombus formation, restenosis, and neointima formation.
- Tissue plasminogen activator genotypes are not associated with susceptibility to chronic periodontitis in Turkish subjects.
- the PAI-1 -675 4G/5G polymorphism may have a role in progression of breast cancer
- This report describe 2 female cousins with neonatal stroke. One was heterozygous for the plasminogen activator inhibitor-1 4G variant and compound heterozygous for the A1298C and C677T methylenetetrahydrofolate reductase mutations.
- SERPINE1 haplotypes are mildly associated with plasma levels of PAI-1 and with the risk of myocardial infarction in nonsmokers. They are also associated with insulin levels and BMI.
- a novel role for the plasminogen activation system in the regulation of fibroblast apoptosis and a potential role of TGF-beta1/PAI-1 in promoting (myo)fibroblast survival in chronic fibrotic disorders.
- No statistically significant differences have been detected about the ratios of genotypes resulting from PAI-1 promotor 4G/5G gene polymorphism in PCOS.
- Children with the plasminogen activator inhibitor-1 4G/4G genotype have an increased risk of more frequent acute otitis media episodes compared with those who are homozygous for the 5G variant.
- Heart rate recovery after exercise was inversely correlated with plasminogen activator inhibitor 1 (PAI-1) activity, tissue plasminogen activator (t-PA) antigen, and fibrinogen
- The protective effect of 4G allele against stroke suggests involvement of PAI-1 4G/5G polymorphism in stroke through a mechanism not related to fibrinolysis, possibly involving altered plaque stabilization, and/or through antagonism of tPA effects.
- The 4G/4G polymorphism of PAI-1 is likely to be associated with ischemic stroke, although the direction of the effect is not consistent from study to study, possibly due to LD with a causative allele and/or stroke heterogeneity.
- inverse correlation between PAI-1 and TAFI antigen levels was found in hyperthyroidism
- Inhibition of urokinase plasminogen activator by PAI-1 reveals a cryptic high-affinity site within the PAI-1 moiety for the VLDLr (very-low-density-lipoprotein receptor), which sustains cell signalling events initiated by binding of uPA to its receptor.
- there is a correlation between the 4G4G genotype of the PAI-1 gene and development of disseminated intravascular coagulation in meningococcal infection
- Significant positive correlations are found between omental tumor necrosis factor (TNF)-alpha protein and plasma PAI-1 levels in obesity subjects.
- CREB binding to the HIF-1 responsive elements in PAI-1 promoter mediates the glucagon effect in the liver
- Plasminogen activator inhibitor-1 4G4G genotype is associated with myocardial infarction but the genotype has a protective effect against development of high grade stable coronary stenoses.
- TAFI and PAI-1 polymorphism determinations were performed by restriction fragment length polymorphism mapping and conventional sequencing
- Genotypes associated with increased expression of PAI-1 were associated with increased susceptibility to community-acquired pneumonia in elderly whites.
- Results demonstrated that the E-box at -566 bp to -561 bp is the negative regulatory element, and the specific and constitutive binding of the upstream stimulating factor-1 to this E-box is the key mechanism of the negative regulation of PAI-1 expression
- PAI-1 may regulate the temporal cadence of cell cycle progression in replicatively competent cell in injury repair
- The 4G/5G polymorphism on PAI-1 levels is controversial and shows the levels of platelet mRNA are related to its content of PAI-1 protein, not 4G/5G promoter polymorphism and platelet PAI-1 mRNA or protein expression.
- Low activity of PAI-1 has been associated with bleeding complications in surgery. The present study evaluated whether low PAI-1 activity is associated with increased fibrinolytic activity in plasma from patients with bleeding compl.
- Suggest an association of A/A -844 PAI-1 genotype with high PAI-1 mRNA expression in rheumatoid arthritis patients.
- The presence of the 4G allele at the PAI-1 gene promoter is associated with higher levels of PAI-1 in response to dietary fat consumption.
- PAI-1 activity levels seem to be related to the small LDL phenotype in patients with type 2 diabetes.
- The antithrombotic effect of rosiglitazone is mediated, at least in part, through the suppressive effect of adiponectin on PAI-1 production.
- No significant correlation between PAI-1 polymorphism and 4G allele carriage in hepatopulmonary syndrome.
- C-reactive protein significantly increases expression of PAI-1 in human coronary artery endothelial cells and in other endothelial cells.
- A deletion/insertion (4G/5G) polymorphism in the promoter region of the PAI-1 gene has been correlated with levels of plasma PAI-1. The 4G allele is associated with higher levels of PAI-1, and might increase the risk for intravascular thrombosis (Review)
- Vitamin E reduced PAI-1 activity in type 2 diabetic patients.
- PAI-1 may have a pathogenic role in coronary disease
- data collected from this population-based study demonstrate significant sex differences in PAI-1 and critical factors that may influence risk of thrombosis
- TPA DD/PAI-1 4G4G genotype combination has reached a borderline significance for reduced risk for multiple sclerosis
- BMI and fasting blood glucose are independently and positively associated with PAI-1 in the nondiabetic, nonobese general population. Serum AGE was one determinant of PAI-1.
- IL-8 induces imbalances between nitric oxide and endothelin-1, and also between plasminogen activator inhibitor-1 and tissue-type plasminogen activator in cultured endothelial cells
- elevated in polycystic ovary syndrome
- A decrease in body mass index in severe and morbid obesity shows a favourable effect on the fibrinolytic system due to a decrease in plasminogen activator inhibitor type 1 levels, but no influence of 4G/5G polymorphism has been observed
- Ligands interacting with alpha-helix F of PAI-1 demonstrated a potential for the protection of activated protein C from inactivation by PAI-1
- patients with biopsy-proven non-alcoholic steatohepatitis had higher PAI-1 and lower TAFI-Ag expression than controls
- These results suggest that pre-treatment PAI-1 levels are higher in more hypoxic tumours and can predict the response to fractionated irradiation in SCCHN.
- results suggest that TNF-alpha and the local renin-angiotensin system coordinately stimulate PAI-1 production in hepatocytes
- Severely obese women have higher than normal blood levels of PAI=1.
- In a subgroup of normolipidemic postinfarction patients, only the PAI-1 4G/5G polymorphism was associated with recurrent risk from a set of atherosclerosis-associated genetic polymorphisms and blood markers.
- absence of plasminogen activator inhibitor-1 in adipocytes may protect the cells against insulin resistance by promoting glucose uptake and adipocyte differentiation via a decrease in the peroxisome proliferator activated receptor-gamma expression.
- Study showed that PAI-1 4G/5G polymorphism is not a risk factor for pulmonary thromboembolism.
- In patients presenting features of metabolic syndrome, plasma PAI-1 levels were mainly conditioned by the whole-body fat content.
- vitronectin without the somatomedin B domain exhibits residual plasminogen activator inhibitor-1-binding activity
- observations suggest that Glucagon-like peptide-1 (GLP-1) inhibits tumour necrosis factor-alpha (TNF-alpha)-mediated plasmogen activator inhibitor-1 (PAI-1)induction in vascular endothelial cells
- Plasminogen activator inhibitor-1 has a role in coronary in-stent restenosis of drug-eluting stents
- Data show that fibroblastic inflammatory reaction around the biopsy channel affects stromal uPA and PAI-1 expression, which possibly leads to falsely increased enzyme levels in ELISA.
- Each additional copy of the intron 3 PAI-1 gene SERPINE1-5878 polymorphism (rs2227667) was associated with higher log(D-dimer) levels.
- The 4G allele of plasminogen activator inhibitor 1 (PAI-I) renders higher PAI-1 promoter activity in stimulated mast cells by binding to upstream stimulatory factor (USF)-1 with greater affinity than does the 5G PAI-I allele.
- higher PAI-1 plasma level is independently associated with a lower risk of retinopathy but a higher risk of CHD in type 2 diabetes
- PAI-1 has a role in fatty liver and hypertriglyceridemia in familial combined hyperlipidemia, along with apolipoprotein E
- PAI-1 plays a critical role in radiation-induced intestinal damage.
- Childhood obesity contributes to higher PAI-1 and TNFalpha and lower TGFbeta levels, which may accompany insulin resistance and dyslipidemia.
- PAI-1 polymorphism (rs6092) was associated with risk of osteonecrosis complicating acute lymphoblastic leukemia
- After a large dose of alcohol in vivo, the dominant effect was up-regulation of hepatic PAI-1 with suppression of plasmin.
- Sympathetic nerve activity (SNA) in an aging subject leads to an increase in the activity of PAI-1, which indicates that an altered interaction between SNA and PAI-1 activity contributes to increased cardiovascular events in the elderly population.
- Synergistic and cumulative effects of polymorphisms between the PAI-1 5G allele and contemporaneous C allele of IL-6 with smoking determine the associated risk of cardiovascular disease.
- PAI-1 is significantly downregulated in PASMC in IPAH, on the mRNA and protein level.
- Cobalt-protoporphyrin did not affect PAI-1 gene expression, whereas CoCl2 upregulated PAI-1 mRNA in a dose-dependent manner.
- Metformin addition has beneficial effect on VEGF and PAI-1 levels in obese type 2 diabetic patients in combination with exercise and medical nutrition treatment.
- Data suggest that PANC-1 cells possess intrinsic, PAI-1-sensitive mechanism for promotion of aggregation and differentiation by prolonged exposure to plasminogen and, possibly, additional precursors of PARs agonists.
- PAI-1 mRNA expression levels are significantly down-regulated in pancreatic neoplasms.
- Cyr61 promoted gastric cancer cell invasive ability via an HIF-1alpha-dependent up-regulation of PAI-1.
- Authors found significantly higher serum levels in patients with high-grade gliomas than in those with low-grade tumors. High-grade glioma patients with a low serum level of PAI-1 survived significantly longer than those with high levels.
- The 4G/5G polymorphism located in the promoter region of PAI-1 gene was associated with prognosis of coronary artery disease patients, and may be regarded as a biomarker of the severity of the involved vessels.
- The PAI-1 genotype distribution was similar in endometriosis patients and controls. PAI-1 levels in endometrial tissue and peritoneal fluid seem to be associated with PAI-1 4G/5G polymorphism in controls.
- structural analysis of PAI-1 and its interaction with vitronectin
- data identify PAI1 as a novel regulator of fibronectin matrix assembly, and indicate that this regulation occurs through a previously undescribed crosstalk between the alphavbeta5 and alpha5beta1 integrins
- Actuarial kidney graft survival was significantly reduced in the 4G/4G donor group (107 months versus 147.5 months, P = 0.013), while recipient PAI-1 genotype did not show any influence on graft survival.
- Compared to PAI-1 protein levels, Chalkley counts and MIB-1, HER2+ and mutations of TP53 were the strongest independent markers of poor prognosis irrespective of nodal statusin breast cancer.
- In lymphocytes obtained from healthy persons more t-PA and PAI-1 was detected than in lymphocytes from patients with chronic lymphoid leukemia
- a novel role for p53 as an mRNA-binding protein that regulates increased PAI-1 expression and stabilization of PAI-1 mRNA in human lung epithelial and carcinoma cells
- The presence of the 4G allele was associated with renal deterioration and increased cardiovascular as well as other vascular events in primary membranous nephropathy.
- the occurrence of PAI-1 4G/4G or 4G/5G genotypes, respectively, is clinically significant for the pathogenesis of venous thromboembolism in pregnancy but not for early abortion
- platelets may be the main source of plasma PAI-1 in lean individuals
- The results of this study support previous observations linking PAI-1 with airway remodeling and uPA with cellular inflammation. Moreover, the observed effect of uPA seems to be independent of its fibrynolytic activity.
- These findings suggest that the upregulation of PAI-1 in H. pylori-infected gastric epithelial cells may contribute to the carcinogenic process.
- Paionin-4 inactivates PAI-1 by a mechanism clearly different from other peptides, small organochemical compounds, or antibodies.
- Comparative proteomic analysis of PAI-1-derived endothelial microparticles is reported.
- Higher plasma PAI-1 levels in ST deviation myocardial infart patients may contribute to the predilection of these patients to occlusive thrombi and ST elevation
- The results indicate that oxVLDL increased PAI-1 expression, and HSF1 mediates the transcription of PAI-1 in cultured vascular endothelial cells or fibroblasts.
- Report increased expression of PAI-1 by Helicobacter pylori in gastric epithelial cells.
- PAI-1 levels were elevated in hemodialysis patient, 4G/5G polymorphism being the most prevalent variant. Patients with PTFE grafts and the 4G/6G variant may have increased thrombosis risk.
- induction of PAI-1 by TGFbeta is critical for the induction of proliferation arrest.
- PAI-1 4G/5G itself is unlikely to be a major risk factor among Caucasian patients with primary open-angle glaucoma.
- Presence of type 2 diabetes significantly modulates the vascular risk conferred by the PAI-1 -675 4G/5G polymorphism in angiographied coronary patients
- PAI-1 is an independent prognostic factor in particular in pN0 breast ductal carcinoma.
- Hypoadiponectinemia & elevated plasminogen activator inhibitor-1 levels were closely associated with metabolic syndrome & its components, inverse relationship was present between adiponectin & PAI-1 levels in metabolic syndrome.
- analysis of a site on PAI-1 that binds to vitronectin outside of the somatomedin B domain
- Investigation of the association between PAI-1 gene 4G/5G polymorphism frequency and plasma TPA enzyme activity in patients with acute stroke reports that there is no direct relation.
- Results indicate that ghrelin inhibits both basal and TNF-alpha-induced PAI-1 production via NF-kappaB pathway in HepG2 cells.
- the C allele of CD14 & the 4G allele of SERPINE1 were encountered more in house dust mite-allergic asthmatic patients than controls; results indicate PAl-1 & CD14 may interact to affect susceptibility to allergic asthma
- SERPINE1 genetic variants may play a role in major depressive disorder susceptibility and in the acute therapeutic response to selective serotonin reuptake inhibitors
- PAI-1 overexpression was significantly associated with malignancy of gastric cancers
- LOX-1, H-Ras, and Raf-1/ERK1/2 are implicated in PAI-1 expression induced by oxidized LDLs or LDL in cultured vascular endothelial cells.
- Established liver fibrosis patients had an improvement in necroinflammatory index after pirfenidone treatment when correlated with plasminogen activator inhibitor-1 and angiotensinogen-6 genotypes.
- Enhanced expression of PAI-1 is associated with the invasion of glioblastoma.
- Increased plasma PAI-1 levels in CD36 deficiency may be due to abnormal fatty acids metabolism.
- The 4G allele in the PAI-1 gene has a negative impact on local recurrence and disease-free survival of Turkish patients with clinical T12N0M0 IDC.
- Both overexpression of plasminogen activator inhibitor-1 (PAI-1) and elevated collagen accumulation are intrinsic features of keloid fibroblasts.
- Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis.
- relationship between exocytosed, membrane-retained tPA and PAI-1, which would modulate cell surface-associated fibrinolytic potential.
- t-PA and PAI-1 levels are determined by both genetic loci of the fibrinolytic and renin-angiotensin systems and other factors often associated with cardiovascular disease
- Pregnancy is associated with major perturbations of endogenous fibrinolytic capacity with an overwhelming increase in plasma PAI-1 concentrations and an inadequate release of active t-PA
- PAI1 mRNA and protein activity are constitutively up-regulated in asthmatic epithelium and play functional roles in both proliferation and repair of healthy cells. In asthmatic cells, elevated PAI1 levels fail to stimulate epithelial repair.
- Upregulation of PAI-1 is associated with invasive breast cancer.
- analysis of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases
- Rac-1 promotes pulmonary artery smooth muscle cell proliferation by upregulation of plasminogen activator inhibitor-1: role of NFkappaB-dependent hypoxia-inducible factor-1alpha transcription.
- PCR confirms maspin and PAI-1 mRNAs exhibit greatest NO-induced induction, which occurred in a p53-dependent manner in a tumor cell line.
- PAI-1 is a major player in the pathogenesis of many vascular diseases as well as in cancer. Review.